Suppr超能文献

从日本刺参(Stichopus japonicus Selenka)中提取的糖胺聚糖解聚片段的抗血栓和抗凝活性

Antithrombotic and anticoagulant activity of depolymerized fragment of the glycosaminoglycan extracted from Stichopus japonicus Selenka.

作者信息

Suzuki N, Kitazato K, Takamatsu J, Saito H

机构信息

Taiho Pharmaceutical Co., Ltd, Tokushima, Japan.

出版信息

Thromb Haemost. 1991 Apr 8;65(4):369-73.

PMID:1647552
Abstract

The antithrombotic and anticoagulant activities of depolymerized fragment (DHG-1) of glycosaminoglycan extracted from Stichopus japonicus Selenka (FGAG) were compared with those of unfractionated heparin (UFH) or low molecular weight heparin (LMWH). DHG-1 at more than 0.3 mg/kg i.v. significantly prevented death of mice treated with thrombin (800 U/kg i.v.). Under the same conditions, FGAG, UFH and LMWH significantly prevented death of mice at more than 0.3, 0.3 and 0.6 mg/kg i.v., respectively. In normal plasma, the concentration required to double the activated partial thromboplastin time (doubling APTT) of DHG-1, FGAG, LMWH and UFH were 12.0, 2.4, 5.8, and 1.2 micrograms/ml, respectively. In antithrombin III (AT III)-depleted plasma, doubling APTT of DHG-1, FGAG, and UFH were 11.3, 2.1, and 18.5 micrograms/ml, respectively. Prothrombin activation in contact-activated plasma was inhibited completely for 60 s at doubling APTT by all glycosaminoglycans used in this study. DHG-1, however, showed much less antithrombin activity than UFH as tested by thrombin clotting time in plasma and chromogenic assay in the presence of AT III. Moreover, DHG-1 showed much less inhibitory activity on factor Xa, factor IXa, and glass surface-induced factor IXa generation than UFH. These results suggested that DHG-1 is one of the promising antithrombotic agents with quite different anticoagulant property from UFH or LMWH.

摘要

将从日本刺参(Stichopus japonicus Selenka)中提取的糖胺聚糖解聚片段(DHG-1)的抗血栓形成和抗凝活性与普通肝素(UFH)或低分子量肝素(LMWH)进行了比较。静脉注射剂量超过0.3 mg/kg的DHG-1可显著预防用凝血酶(800 U/kg静脉注射)处理的小鼠死亡。在相同条件下,FGAG、UFH和LMWH分别在静脉注射剂量超过0.3、0.3和0.6 mg/kg时可显著预防小鼠死亡。在正常血浆中,使DHG-1、FGAG、LMWH和UFH的活化部分凝血活酶时间加倍(使APTT加倍)所需的浓度分别为12.0、2.4、5.8和1.2微克/毫升。在抗凝血酶III(AT III)缺乏的血浆中,使DHG-1、FGAG和UFH加倍APTT的浓度分别为11.3微克/毫升、2.1微克/毫升和18.5微克/毫升。本研究中使用的所有糖胺聚糖在使APTT加倍时,均可在60秒内完全抑制接触激活血浆中的凝血酶原激活。然而,通过血浆中的凝血酶凝血时间和在AT III存在下的发色底物法检测,DHG-1的抗凝血酶活性比UFH低得多。此外,与UFH相比,DHG-1对因子Xa、因子IXa以及玻璃表面诱导的因子IXa生成的抑制活性要低得多。这些结果表明,DHG-1是一种有前景的抗血栓形成药物,其抗凝特性与UFH或LMWH有很大不同。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验